evipedia.ai
← Back

LSD for Health & Longevity

Evidence Review created on 10/01/2026 using AI4L / Opus 5.5

Also known as: Lysergic acid diethylamide, Lysergide, LSD-25, Delysid, MM120, DT120, Acid

Motivation

LSD (lysergic acid diethylamide) is a compound first made in the laboratory from a grain fungus in 1938. Taken orally in amounts measured in millionths of a gram, it profoundly alters perception, mood and thought for most of a day. It acts mainly on one type of serotonin receptor in the brain. Interest among health-focused adults centers on two uses: a single, closely supervised full dose for lasting relief from anxiety and low mood, and repeated tiny “microdoses” taken to support mood and well-being.

LSD was widely studied in psychiatry during the 1950s and 1960s before nearly every country banned it. Research resumed in the 2010s, and a drug company is now running large late-stage trials of a tablet form for anxiety and depression. At the same time, microdosing has spread through technology and wellness communities, and laboratory studies have begun asking whether this drug class touches the biology of aging.

This review examines the human evidence for and against LSD as a tool for mental health and longevity, the risks for people without and with psychiatric or heart conditions, and the practical, legal and monitoring considerations of its use.

Benefits - Risks - Protocol - Conclusion

This section lists high-level expert discussions of LSD, psychedelic microdosing and the psychedelic therapy model LSD belongs to.

Life Extension Magazine’s depression protocol includes a short paragraph on LSD’s antidepressant research, but it is not listed: the five-item limit was reached by the other priority experts, whose items discuss LSD or the psychedelic class at greater length.

Grokipedia

LSD

An encyclopedic overview of LSD’s chemistry, pharmacology, history, therapeutic research and legal status; useful background, though AI-generated and not peer reviewed.

Examine

LSD

A short evidence summary describing LSD’s preliminary support for depression and anxiety, with a research feed of study summaries; most study details require a paid subscription.

ConsumerLab

No ConsumerLab article on LSD exists. ConsumerLab tests dietary supplements and foods; LSD is neither a supplement nor an approved prescription drug but a controlled substance, which falls outside its coverage.

Systematic Reviews

This section lists systematic reviews and meta-analyses on LSD’s efficacy for alcohol misuse, depression and other psychiatric disorders, and on its adverse effects.

Mechanism of Action

LSD is a partial agonist (a molecule that switches a receptor on, though not to full capacity) at the serotonin 2A receptor (5-HT2A), which is dense on neurons of the cerebral cortex. Activation increases release of glutamate (the brain’s main excitatory messenger) and loosens the organization of brain networks, including the default mode network (regions active during self-focused thought), tracking the altered perception of the experience (Liechti, 2017; the Basel group later licensed its LSD data to the developer MindMed). Pretreatment with ketanserin (a 5-HT2A blocker) abolishes most acute effects.

LSD is not selective: it also binds other serotonin receptors (5-HT1A, 5-HT2C), dopamine receptors and 5-HT2B (a serotonin receptor on heart valves). Its long action reflects unusually slow release from the receptor, which closes a “lid” over the molecule (Wacker et al., 2017).

Two explanations compete for its lasting effects. One holds that the 5-HT2A-driven experience and its psychological processing produce change; the other proposes that LSD binds TrkB (the receptor for brain-derived neurotrophic factor, BDNF, a growth signal for neurons), promoting neural plasticity independently of 5-HT2A; this rests on cell and mouse data (Moliner et al., 2023).

Oral LSD peaks in blood after about 1.5 hours, has a half-life of 3.6–4.1 hours, distributes widely into tissues (about 38 liters) and acts for 7–12 hours (Holze et al., 2021). Several liver enzymes metabolize it, mainly to the inactive 2-oxo-3-hydroxy-LSD; CYP2D6 (an enzyme that breaks down many drugs) has the largest measured influence on exposure (Vizeli et al., 2021).

Historical Context & Evolution

Albert Hofmann synthesized LSD at Sandoz in 1938 while seeking a circulatory stimulant, discovering its psychoactive effects in 1943. Sandoz distributed it as Delysid for psychiatric research, first as a “model psychosis” tool, then for two therapy styles: psycholytic therapy (repeated moderate doses to aid talk therapy, associated with Stanislav Grof) and psychedelic therapy (one high dose aiming at a transformative experience, associated with Humphry Osmond and Abram Hoffer). Nearly 10,000 scientific papers followed (Passie et al., 2008). Controlled trials in alcoholism reported reduced drinking, a finding later confirmed by meta-analysis, although those trials lacked modern blinding and reporting standards.

Recreational spread, covert government experiments and political backlash led the US to list LSD in Schedule I (the most restrictive category, reserved for drugs without accepted medical use) in 1970, followed by international control in 1971. Research then stopped for decades for regulatory rather than evidential reasons.

Modern research restarted in Switzerland in the 2010s with studies of anxiety in serious illness, pharmacology and brain imaging (Liechti, 2017). In parallel, microdosing spread in technology and wellness circles after James Fadiman’s 2011 book described a one-day-on, two-days-off schedule. Since 2020, the developer MindMed (now Definium Therapeutics), which holds exclusive rights to the Basel LSD data, has run late-stage trials of a tablet form for anxiety and depression. Longevity interest grew from mental-health links to aging and early animal lifespan data, while supportive and null findings both accumulate.

Expected Benefits

High 🟩 🟩 🟩

Reduced Anxiety, Including Distress in Serious Illness

A single supervised dose brought rapid, durable relief in generalized anxiety disorder. A phase 2b (mid-stage, dose-finding) trial of 198 adults found 100–200 µg, but not 25–50 µg, superior to placebo at four weeks; two phase 3 (large confirmatory) trials (Voyage, Panorama) reported 12-week benefit, so far only as company announcements. All three were sponsored by the developer MindMed (now Definium Therapeutics). A Basel trial of 42 patients, including people with life-threatening illness, showed benefit to 16 weeks; MindMed holds exclusive rights to Basel’s LSD data.

Magnitude: On the Hamilton Anxiety Rating Scale (HAM-A, a 0–56 clinician-rated scale), placebo-adjusted change of −5.0 (100 µg) and −6.0 (200 µg) points at week 4 against a minimal important difference (the smallest change patients notice) of 2.5; −5.4 (Voyage, response 43% vs 16%) and −5.1 (Panorama) at week 12; Basel trial effect size d = −1.18 (Cohen’s d, a standardized effect size where 0.8 is large).

Reduced Depressive Symptoms

The developer-sponsored Emerge phase 3 trial (149 adults with major depressive disorder, one 100 µg dose) reported rapid improvement lasting 12 weeks, so far only in a press release. In an independent Basel trial of 61 patients, 100 µg plus 200 µg with supportive therapy beat 25 µg twice on clinician ratings, but the self-rated primary endpoint narrowly missed significance. Most participants can tell whether they received the drug, so expectancy may inflate effects, a concern quantified in a network meta-analysis (a pooled comparison of several treatments).

Magnitude: Montgomery–Åsberg Depression Rating Scale (MADRS, 0–60) placebo-adjusted change −8.1 points at week 6 (remission 24% vs 3%) and −7.3 at week 12 (Emerge); clinician-rated Inventory of Depressive Symptomatology difference −9.2 points (95% confidence interval, the range likely to contain the true effect, −17.1 to −1.3) in the Basel trial.

Reduced Alcohol Misuse

A meta-analysis of six randomized trials (536 participants) found that a single high dose given within alcoholism treatment programs reduced alcohol misuse, with no inconsistency between trials. A 2025 systematic review confirmed a small effect across substance use disorders. The trials date from the 1960s and predate modern blinding and reporting standards. For health-focused adults the relevance lies in curbing drinking above health targets.

Magnitude: Odds ratio (how much more likely improvement was with LSD than control) 1.96 (95% confidence interval 1.36–2.84) for reduced alcohol misuse; standardized mean difference (effect in standard-deviation units) 0.19 across substance use disorders.

Medium 🟩 🟩

Reduced Pain Sensitivity

In a placebo-controlled crossover trial of 24 healthy volunteers, 20 µg, a dose below the threshold for a full psychedelic experience, increased tolerance of near-freezing water and lowered pain and unpleasantness ratings; 5 and 10 µg did not. A patient survey reported ended cluster headache (recurring bouts of severe one-sided head pain) periods after LSD. Studies from the 1960s–1970s, such as Kast & Collins, 1964, reported pain relief from full doses in seriously ill patients, but no modern placebo-controlled trial in patients has been completed.

Magnitude: Treatment explained 9% of the variance in cold-water pain tolerance (partial eta-squared 0.09), with only the 20 µg dose separating from placebo; in the survey, 7 of 8 LSD users with cluster headache reported ending a cluster period.

Longer Sleep After Microdoses

In a six-week randomized trial of 80 healthy men self-administering 10 µg every third day, wearable trackers recorded longer sleep on the night after each dose, with no lost sleep on dosing days and no change in sleep stages. Only men were studied, and whether the extra sleep reflects benefit or a greater sleep need is unclear.

Magnitude: 24.3 additional minutes of sleep per night (95% confidence interval 10.3–38.3) on post-dose nights versus placebo, across 3,231 recorded nights.

Low 🟩

Microdosing for Mood, Focus and Cognition ⚠️ Conflicted

A home-dosing trial found better mood on dose days only. Laboratory and self-blinded trials found no benefit beyond placebo, and an attention-deficit/hyperactivity disorder (ADHD) trial was negative. Net reading: no lasting benefit beyond expectancy has been shown.

Magnitude: In ADHD, symptom change was −7.1 points with 20 µg versus −8.9 with placebo (no difference); 191 self-blinded microdosers showed no between-group differences in psychological outcomes.

Lasting Well-Being in Healthy Adults

In a 12-month follow-up of 16 healthy volunteers given 200 µg in a laboratory, participants attributed higher well-being, life satisfaction and positive social effects to the session; personality scores did not change. The follow-up was uncontrolled and self-attributed.

Magnitude: At 12 months, 10 of 14 participants rated the session among the ten most meaningful experiences of their lives; the study reports statistically significant rises in well-being ratings without an effect size.

Lower Cardiometabolic Disease Odds in Psychedelic Users

US survey data linked lifetime use of classic psychedelics, including LSD, with lower odds of heart disease and diabetes, and another analysis with better self-rated health and less obesity. These single-timepoint surveys cannot separate drug effects from user characteristics.

Magnitude: Adjusted odds ratio 0.77 (95% confidence interval 0.65–0.92) for past-year heart disease and 0.88 (0.78–0.99) for diabetes among lifetime users.

Speculative 🟨

Neuroplasticity and Brain Resilience

LSD grew neuronal connections in cell and rodent studies, raised plasma BDNF in healthy volunteers and altered white-matter imaging in depressed patients. These are unvalidated markers; no brain-aging outcome has been tested.

Extended Lifespan

A preprint reported longer lifespan and a caloric-restriction-like metabolic state in Caenorhabditis elegans (a roundworm) given LSD. The basis is animal-only and not yet peer reviewed; no mammalian or human data exist.

Protection Against Neuroinflammation and Dementia

Anti-inflammatory serotonin 2A signaling in animals motivated a safety trial in older adults run by Eleusis, a company developing LSD for Alzheimer’s disease. The basis is mechanistic only; no human outcome data exist.

Benefit-Modifying Factors

  • Genetic variation in CYP2D6: People with no functional CYP2D6 (poor metabolizers, roughly 5–10% of Europeans) had about 75% higher LSD exposure and stronger, longer effects (Vizeli et al., 2021), so the same dose may deliver more benefit and more side effects.
  • Baseline symptom severity: Benefits in trials were shown in people with moderate to severe anxiety or depression. Adults with depressed mood reported stronger positive effects from a 26 µg dose, while healthy adults gained little from microdosing.
  • Baseline biomarkers: No blood or imaging biomarker has been validated to predict benefit; plasma BDNF rises after LSD but has not been tied to clinical response. Baseline symptom-scale scores remain the only measured predictor of response.
  • Sex: A controlled dose-response study found no sex differences in blood levels or effects. Several microdosing trials enrolled only men, so findings for women rest on less data.
  • Pre-existing conditions and medications: Ongoing antidepressants that raise serotonin may blunt or alter the response; daily paroxetine left pleasant effects intact but reduced anxiety and nausea. Benefits for anxiety extended to people with life-threatening illness.
  • Age: Microdoses of 5–20 µg were well tolerated in adults aged 55–75 without balance or cognitive impairment. Phase 3 trials enrolled adults up to 74; efficacy data beyond that age are lacking.
  • Expectancy and setting: Expectations and supportive surroundings shape outcomes; in a self-blinded study, microdosing benefits were explained by participants guessing their allocation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Acute Anxiety and Challenging Experiences

Anxiety, paranoia and frightening perceptions during the session are the most characteristic risk. In a dose-finding trial, 200 µg, unlike 100 µg, caused significant anxiety; anxiety led 4 of 40 microdosers to withdraw; and a meta-analysis found anxiety among the common adverse events in clinical studies. Episodes are usually transient under supervision but can lead to dangerous behavior when unsupervised.

Magnitude: 10% (4 of 40) withdrew for anxiety at 10 µg microdoses; one treatment-related serious adverse event (acute transient anxiety) occurred among 42 patients (2%) after 200 µg in the Basel anxiety trial.

Nausea, Headache and Perceptual Disturbance

In the phase 2b trial, visual illusions, nausea and headache rose with dose and resolved within the dosing day. Fatigue, dizziness and reduced appetite are also reported, and a drug reference monograph lists tremor and insomnia.

Magnitude: At 100 µg versus placebo: visual perceptual changes 92.5% vs 10.3%, nausea 40.0% vs 7.7%, headache 35.0% vs 23.1%.

Raised Blood Pressure, Heart Rate and Body Temperature

LSD is a mild sympathomimetic (mimicking the body’s fight-or-flight stimulation). Controlled trials show blood pressure rising from 50 µg and heart rate from 100 µg, and even 20 µg raised blood pressure; body temperature also rises, mostly at higher doses. A microdosing review lists raised blood pressure among the most common effects. The rise is transient but relevant for people with cardiovascular disease.

Magnitude: In a pooled analysis of 83 healthy subjects, peak heart rate exceeded 100 beats per minute in 0%, 6%, 20% and 25% of subjects at 25, 50, 100 and 200 µg, and peak body temperature exceeded 38 °C in 0%, 11%, 7% and 34%; no subject’s systolic blood pressure exceeded 180 mmHg.

Medium 🟥 🟥

Psychosis, Mania and Serious Psychiatric Events ⚠️ Conflicted

A meta-analysis found serious adverse events (worsening depression, suicidal behavior, psychosis) in about 4% of trial participants with psychiatric disorders and none in healthy volunteers. In Ontario health records, hallucinogen-related emergency visits preceded higher schizophrenia rates, yet a US population study of 130,152 adults found no link between lifetime LSD use and psychosis. The studies differ because emergency visits select heavy or problematic use in vulnerable people, while the survey counted any lifetime use. Net reading: risk concentrates in people with psychotic or bipolar vulnerability.

Magnitude: Serious adverse events in about 4% of participants with neuropsychiatric disorders versus 0% of healthy participants; adjusted hazard ratio (relative rate over time) 3.53 (95% confidence interval 3.05–4.09) for schizophrenia spectrum disorder after a hallucinogen-related emergency visit.

Low 🟥

Persistent Visual Disturbances

Hallucinogen persisting perception disorder (HPPD; recurring drug-free visual distortions) is documented mainly in surveys of recreational users, with greater risk at higher cumulative LSD exposure. No cases appeared in contemporary trials, and symptoms are usually mild.

Magnitude: 4.2% of 2,455 surveyed hallucinogen users reported visual symptoms distressing enough to consider treatment; 60.6% reported any drug-free hallucinogen-like visual experience.

Seizures

Convulsive episodes appear among rare serious adverse events in patient populations, and online reports link seizures strongly to concurrent lithium use. Evidence is uncontrolled.

Magnitude: 47% of 62 online reports of LSD or psilocybin taken with lithium described seizures, versus none of 34 reports with lamotrigine.

Injury and Death From Impaired Judgment

LSD has no established lethal dose, but a forensic review traced deaths attributed to it to massive overdoses, physical restraint during agitation, or substituted drugs. Impaired judgment during unsupervised use creates accident risk.

Magnitude: Not quantified in available studies. No study has measured injury rates per exposure; the evidence consists of case reports and forensic reviews.

Counterfeit Product

Blotter paper sold as LSD may contain NBOMe compounds (potent synthetic hallucinogens). A review links them to seizures, overheating and deaths not seen with LSD itself.

Magnitude: In blotters seized in one Brazilian state, the share containing LSD fell from 100% in 2011 to 0.1% in 2014 and 17.6% in 2017, replaced mainly by NBOMe and other synthetic hallucinogens; rates vary by market and year.

Speculative 🟨

Heart Valve Damage With Repeated Dosing

LSD strongly activates 5-HT2B, the receptor behind valve damage from the withdrawn diet drug fenfluramine. A systematic review found no human cases; the basis is mechanistic, and echocardiograms (heart scans) stayed normal after 16 microdoses.

Risk-Modifying Factors

  • CYP2D6 genotype: Poor metabolizers reach about 75% higher LSD levels with longer effects (Vizeli et al., 2021), raising the chance of anxiety and prolonged sessions at standard doses.
  • Family history as genetic liability: A first-degree relative with schizophrenia or bipolar disorder signals inherited vulnerability; trials exclude such people because psychotic and manic reactions cluster in this group.
  • Baseline blood pressure and heart status: Elevated resting blood pressure, arrhythmia (irregular heart rhythm) or existing valve disease magnify the cardiovascular strain of a session; trials typically exclude uncontrolled hypertension.
  • Sex: Blood levels and acute effects did not differ by sex in a controlled study. Safety in pregnancy and breastfeeding is unknown.
  • Pre-existing conditions: Personal history of psychosis, mania, seizures or suicidal crises, and current lithium treatment, carry the highest risk; anxiety-prone temperament raises the chance of a distressing session.
  • Age: Older adults tolerated microdoses well, but have less cardiovascular reserve and higher fall risk during perceptual distortion; data above 75 are lacking.

Key Interactions & Contraindications

  • Lithium: Absolute contraindication. Co-use was linked to seizures in about half of reports; trial protocols require lithium to be stopped under psychiatric supervision before dosing.
  • SSRIs and SNRIs (common antidepressants that raise serotonin, and for SNRIs also norepinephrine; e.g., sertraline, escitalopram, paroxetine, venlafaxine): Caution. A 1996 interview study described blunted effects; daily paroxetine raised LSD exposure 1.4–1.5-fold yet reduced anxiety and nausea. Monitoring rather than dose change was suggested.
  • Strong CYP2D6 inhibitors (bupropion, quinidine, terbinafine): Caution; higher and longer LSD exposure, mimicking the poor-metabolizer state. Lower doses reduce the risk of prolonged sessions; for CYP2D6-inhibiting SSRIs such as paroxetine, the trial above found no dose change necessary.
  • Tricyclic antidepressants (older antidepressants, e.g., amitriptyline, imipramine): Caution; reported to intensify physical and psychological responses. Clinical protocols taper them before dosing.
  • MAO inhibitors (antidepressants that block monoamine oxidase, an enzyme that breaks down serotonin and dopamine; e.g., phenelzine, tranylcypromine): Monitor; reported to weaken LSD effects, prompting risky re-dosing. Avoiding re-dosing within a session prevents excess exposure.
  • Antipsychotics and 5-HT2A blockers (risperidone, olanzapine, quetiapine, ketanserin, trazodone): Monitor; they blunt or abolish effects, negating the intended response. Trials require a supervised washout before dosing; ketanserin and benzodiazepines (sedatives such as lorazepam) serve as rescue medication.
  • Stimulants and sympathomimetics (amphetamine, methylphenidate, cocaine, MDMA): Caution; additive rises in blood pressure and heart rate. Combinations are excluded from clinical protocols.
  • Over-the-counter decongestants (pseudoephedrine, phenylephrine) and dextromethorphan (a cough suppressant): Caution; decongestants add blood-pressure stimulation and dextromethorphan adds serotonin-raising and dissociative (detachment from surroundings and self) effects. Avoidance on dosing days removes the overlap.
  • Supplements with additive stimulation (yohimbine, synephrine, high-dose caffeine): Caution; additive blood-pressure, heart-rate and anxiety effects. Omitting them on dosing days limits cardiovascular strain.
  • Serotonin-raising supplements (St. John’s wort, 5-HTP (5-hydroxytryptophan, a serotonin building block), SAMe (S-adenosylmethionine, a natural compound sold as a mood supplement)): Monitor; theoretical additive serotonin effects and, for St. John’s wort, altered drug metabolism. Pausing them around sessions avoids unpredictable responses.
  • Alcohol and cannabis: Caution; alcohol impairs judgment and coordination, and cannabis can intensify anxiety and psychotic-like reactions. Abstinence for 24 hours around dosing is standard in trials.
  • Other interventions: Caution; driving and hazardous work during residual effects risk accidents, so trials exclude them for 24 hours. Preparation and integration psychotherapy are part of trial protocols and may enhance benefit.

Populations who should avoid LSD:

  • Personal history of schizophrenia, other psychotic disorders or bipolar I disorder, or a first-degree relative with these conditions
  • Current suicidal ideation with intent or a suicide attempt within the past 12 months
  • Uncontrolled hypertension (≥140/90 mmHg on repeated readings despite treatment)
  • Recent heart attack or stroke (<6 months), unstable angina (chest pain at rest or worsening), significant arrhythmia, or known valvular heart disease (moderate or worse)
  • Epilepsy or prior unexplained seizures
  • Current lithium therapy
  • Pregnancy or breastfeeding
  • Severe liver impairment (Child-Pugh Class C, the most severe liver-function category)
  • People without a sober, trained person present or in unsafe environments

Risk Mitigation Strategies

  • Psychiatric screening: Trials screen personal and family history for psychosis, bipolar disorder and suicidality before dosing, preventing most serious psychiatric reactions, which cluster in vulnerable people.
  • Dose ceiling of 100 µg: Positive effects plateau at 100 µg; anxiety and ego dissolution (loss of the sense of self) keep rising at 200 µg (Holze et al., 2021); staying at or below 100 µg limits challenging experiences.
  • Supervised setting with a sober monitor: Phase 3 sessions keep participants in clinic until discharge criteria are met, mostly within 8 hours; a trained, sober monitor prevents accidents and injury from impaired judgment.
  • Blood pressure check before dosing: Readings below 140/90 mmHg before dosing and repeated checks during the session limit cardiovascular strain from transient rises in blood pressure and heart rate.
  • Lithium and interacting drug review: Stopping lithium under psychiatric supervision and reviewing antidepressants, stimulants and supplements beforehand prevents seizures and unpredictable drug interactions.
  • Product verification: Reagent testing (Ehrlich reagent turns purple with LSD but not NBOMe compounds) or laboratory drug checking reduces the risk of counterfeit substances.
  • Rescue plan: Clinical protocols keep ketanserin or a benzodiazepine available to ease a severely distressing experience, limiting panic, agitation and resulting injury.
  • Limiting repeated exposure: Capping microdosing courses at 4–8 weeks with breaks, and obtaining an echocardiogram before prolonged courses, limits theoretical valve risk and tolerance.
  • No driving for 24 hours: Excluding driving and hazardous tasks until the day after dosing prevents accidents from residual perceptual and judgment effects.

Therapeutic Protocol

  • Single-dose clinical protocol (Definium Therapeutics): One 100 µg orally disintegrating tablet without psychotherapy, with clinic monitoring until discharge criteria are met (92% by hour 8); used in the phase 3 anxiety and depression trials.
  • LSD-assisted psychotherapy (Liechti group, Basel; Peter Gasser): Two sessions of 100–200 µg, several weeks apart, with preparatory and integration psychotherapy; used for anxiety, depression and illness-related distress.
  • Microdosing (James Fadiman): 5–20 µg, commonly 10 µg, every third day (one day on, two days off) for 4–8 weeks, then a pause; controlled trials (de Wit et al., 2022) have not shown benefit over placebo.
  • Time of day: Full doses are taken in the morning, since effects last 7–12 hours and evening dosing disrupts sleep; microdoses are likewise taken in the morning.
  • Half-life: Plasma half-life is 3.6–4.1 hours (Holze et al., 2021); unusually slow release from the receptor (Wacker et al., 2017) may help explain effects lasting 7–12 hours.
  • Single versus split dosing: Doses are taken as a single administration; split or “booster” dosing within a session is unstudied, and the Basel protocol separates its 100 µg and 200 µg doses into different sessions.
  • CYP2D6 genotype: Poor metabolizers experience higher exposure, so a lower full dose (for example 50–75 µg) may produce comparable effects; genotyping is optional and not yet used routinely.
  • Sex: No sex-based dose adjustment is used, as blood levels and elimination of LSD did not differ by sex; menstrual-cycle effects are being studied in a microdosing trial for premenstrual disorders.
  • Age: Adults up to 74 were included in phase 3 trials; older adults typically start at lower doses with closer blood pressure monitoring because of reduced cardiovascular reserve.
  • Baseline biomarkers: Baseline anxiety and depression scale scores and blood pressure guide eligibility and track response; trials enrolled moderate to severe symptoms.
  • Pre-existing conditions: People on antidepressants have been treated in some studies without tapering; psychiatric comorbidities and cardiovascular disease shift protocols toward lower doses and closer supervision.

Discontinuation & Cycling

  • Short-term, episodic use: LSD is used as one or two sessions or a time-limited microdosing course, not a lifelong daily drug; re-treatment after relapse is being studied in phase 3 extensions.
  • Withdrawal effects: No physical withdrawal syndrome or craving has been documented; LSD is not considered addictive, though some users report low mood or fatigue the day after a session.
  • Tapering: No taper is needed after single doses or microdosing courses, because dependence does not develop.
  • Tolerance and cycling: Tolerance develops within days of daily dosing and largely resets after about one to two weeks, which is why microdosing schedules include off days and multi-week breaks.
  • Spacing of full doses: Full-dose sessions are spaced weeks to months apart, allowing psychological integration and full loss of tolerance.

Sourcing and Quality

  • Legal status determines source: LSD is a Schedule I substance in the US and controlled internationally; legal access is limited to clinical trials and, in Switzerland, restricted compassionate medical use.
  • Pharmaceutical formulations: Trials use GMP-produced (made under pharmaceutical manufacturing standards) LSD base or its tartrate (a stable salt form) in oral solution, or Definium’s orally disintegrating tablet; no product is approved, compounding pharmacies cannot supply it, and a US marketing application is expected in 2027.
  • Variable illicit potency: Blotter paper labeled 100 µg often contains less or more, and LSD degrades with light, heat and moisture, making doses unpredictable.
  • Counterfeit substances: NBOMe and DOx compounds (potent synthetic stimulant hallucinogens) are sold as LSD; Ehrlich reagent testing or laboratory drug-checking services help confirm identity.
  • Volumetric dosing for microdoses: Microdosers dissolve a known dose in distilled water or ethanol and measure out small equal portions, stored cold and dark, because cutting blotter paper gives inaccurate doses.
  • LSD prodrugs: 1P-LSD and 1cP-LSD, sold as research chemicals in some countries, convert to LSD in the body but lack pharmaceutical quality control and occupy a legal grey zone.

Practical Considerations

  • Time to effect: Acute effects begin within 30–60 minutes and peak at 2–3 hours; anxiety and mood improvements appeared by day 2 to week 1 in phase 3 trials (Voyage, Emerge) and persisted to 12 weeks, with Basel follow-up to 12 months.
  • Common pitfalls: Confusing micrograms with milligrams, unverified product, unexpectedly strong “microdoses”, unsupervised full doses, combining with lithium or other drugs, and attributing microdosing benefits that controlled trials attribute to expectancy.
  • Regulatory status: Schedule I in the US with no accepted medical use; the FDA (US Food and Drug Administration) granted Breakthrough Therapy designation (expedited review) to Definium’s tablet for generalized anxiety disorder, with a marketing application planned for early 2027.
  • Cost and accessibility: Illicit LSD is inexpensive but illegal; trials are the only legal US route. Supervised single-dose treatment carries clinic costs, while generic daily antidepressants are low-cost, giving insurers an incentive to favor them, a potential structural bias in guidelines and research funding.
  • Session logistics: A full-dose session occupies 8–12 hours plus a recovery evening, requires a sober companion or clinic monitoring, and excludes driving until the next day.

Interaction with Foundational Habits

  • Sleep: Direct, bidirectional. Full doses taken late delay sleep because effects last up to 12 hours; morning dosing avoids this. Microdosing increased next-night sleep by about 24 minutes (Allen et al., 2024), possibly reflecting greater sleep need.
  • Nutrition: Indirect. No nutrient depletion is known. A light meal before dosing reduces nausea, which affected 40% at 100 µg; an empty stomach speeds onset. Hydration and avoiding alcohol and high-dose caffeine on dosing days limit discomfort and cardiovascular stimulation.
  • Exercise: Indirect, potentially additive for heart rate and blood pressure. Strenuous training during acute effects adds cardiovascular strain and injury risk from altered perception; light walking is generally tolerated. No studies address muscle adaptation; microdose days showed no change in physical activity.
  • Stress management: Direct. LSD acutely raises cortisol (Schmid et al., 2015), yet anxiety fell for up to 16 weeks in a Basel trial. Meditation and breathing practice help prepare for and navigate challenging moments; integration practices consolidate insights.

Monitoring Protocol & Defining Success

Baseline testing before a first full dose or microdosing course establishes eligibility and a reference point: blood pressure and heart rate on repeated readings, an electrocardiogram, liver enzymes, a pregnancy test where relevant, a medication review for lithium and interacting drugs, and validated anxiety and depression questionnaires. An echocardiogram is added before courses of repeated dosing lasting beyond about 8 weeks, given the theoretical valve concern.

Ongoing monitoring follows a set cadence: blood pressure and heart rate before dosing and hourly for the first 8 hours of a full-dose session; symptom questionnaires at 1 day, 1 week, 4 weeks and 12 weeks after dosing, then every 3–6 months; for repeated microdosing, blood pressure weekly and a repeat echocardiogram every 6–12 months while dosing continues.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure <120/80 mmHg Cardiovascular strain risk Conventional target <130/80; trials exclude uncontrolled hypertension; measure seated, after 5 minutes’ rest
Resting heart rate 50–70 bpm Stimulant effect baseline Conventional range 60–100 bpm (beats per minute); pair with blood pressure
Electrocardiogram (QTc) QTc <440 ms (men), <460 ms (women) Rhythm screening ECG (electrical heart tracing); QTc is the heart-rate-adjusted time the heart muscle needs to reset between beats; conventional cut-offs 450/470 ms
Echocardiogram (heart ultrasound) No more than trace valve regurgitation Valve safety with repeated dosing Regurgitation is backflow of blood through a leaking valve; no established LSD-specific target; track change from the individual’s own baseline
ALT and AST ALT <25 U/L; AST <25 U/L Liver clearance capacity ALT/AST are liver enzymes; conventional upper limits about 40 U/L; fasting not required
GAD-7 anxiety score <5 Defines anxiety response GAD-7 is a 7-item generalized anxiety questionnaire; ≥10 indicates clinically relevant anxiety
PHQ-9 depression score <5 Defines mood response PHQ-9 is a 9-item depression questionnaire; ≥10 indicates clinically relevant depression
CYP2D6 genotype Normal metabolizer (no target range) Predicts exposure Optional one-time test; poor metabolizers have about 75% higher exposure

Qualitative markers of success:

  • Stable reduction in everyday worry and rumination
  • Mood and motivation over weeks, not just on dosing days
  • Sleep quality and morning energy
  • Sense of connectedness and quality of relationships
  • Cognitive clarity and focus at work
  • Alcohol intake relative to personal targets
  • Absence of persistent visual disturbances, paranoia or unusual thoughts

Emerging Research

  • Phase 3 anxiety program: Voyage (NCT06741228), 214 participants, and Panorama (NCT06809595), 245 participants, test one 100 µg dose of DT120 against placebo on 12-week anxiety scores (Panorama adds a 50 µg control arm); peer-reviewed publication will show whether developer-announced results hold.
  • Phase 3 depression program: Emerge (NCT06941844), 149 participants, and the recruiting Ascend (NCT07592689), 165 participants, assess single-dose DT120 on depression scores; replication in a second trial is the key test.
  • Alcohol use disorder: A Basel phase 2 trial (NCT05474989, 128 participants) tests whether the 1960s alcoholism findings replicate under modern blinding and reporting.
  • Cluster headache: Two phase 2 trials, NCT03781128 (Basel, 30 participants) and NCT05477459 (Radboud, 65 participants), test whether survey reports of ended attack periods hold under placebo control.
  • Palliative care: NCT05883540, a 60-participant phase 2 trial, measures pain, anxiety, depression and existential distress in serious illness.
  • Microdosing with a noticeable placebo: The LSDDEP2 depression trial (Daldegan-Bueno et al., 2024) uses an active placebo (a dummy substance with noticeable effects) to counter expectancy and is registered only in Australia and New Zealand (no NCT ID); a 150-participant placebo-controlled premenstrual disorder trial (NCT07189299) tests 10 µg daily or every other day in women.
  • Expectancy and blinding: Szigeti & Heifets, 2024 argue that expectancy may inflate psychedelic trial results, a challenge that could weaken efficacy estimates.
  • Valve safety: Xu et al., 2026 flag 5-HT2B-driven valve risk; echocardiographic follow-up of repeated dosing could weaken the case for long microdosing courses.
  • Aging biology: A roundworm lifespan preprint (Carrilho et al., 2025) and white-matter changes in depression (Avram et al., 2026) motivate testing whether LSD affects aging-related outcomes in mammals and people.

Conclusion

LSD is a long-acting psychedelic that acts mainly on one serotonin receptor. The strongest evidence concerns a single supervised full dose for anxiety and depression: several controlled trials, including large late-stage trials, report rapid relief lasting months, and older trials point to reduced problem drinking. The large recent trials and the only trial in older adults were paid for by companies developing the drug; one also holds exclusive rights to the main academic data, and the large trials await independent publication. Participants can usually tell whether they received the drug, which may inflate effects.

For health-focused adults the picture splits sharply by dose. Microdosing, the form most often adopted for daily performance, has not shown lasting benefits beyond expectation in controlled trials, apart from a modest lengthening of sleep. Longevity effects rest on worm experiments, laboratory signs that the brain forms new connections, and surveys of past users, so any direct effect on aging remains unknown.

The main risks are frightening experiences during the session, temporary rises in blood pressure and heart rate, and, in people with a personal or family tendency toward psychosis or bipolar illness, serious psychiatric reactions. Combining it with lithium has been linked to seizures in user reports, though this rests on uncontrolled accounts, illicit products may be counterfeit, and frequent long-term dosing raises an unresolved question about heart valves. Overall, the evidence supports meaningful mental-health effects under supervision, weaker and uncertain evidence for longevity, and a legal status that still limits access.

Top - Benefits - Risks - Protocol